Moderna reports Q1 EPS ($2.52), consensus ($3.18)

Reports Q1 revenue $108M, consensus $115.32M. “In the first quarter, we continued to execute with financial discipline, significantly reducing our operating expenses, and further prioritized our investments in oncology. Looking ahead, we are reiterating our 2025 financial framework and announcing a cost structure that is expected to reduce our annual operating expenses by approximately $1.5 billion by 2027. With several Phase 3 readouts approaching and continued momentum toward 10 product approvals, we remain confident in Moderna’s (MRNA) long-term outlook,” said Stephane Bancel, Chief Executive Officer of Moderna.